Penn Medicine News Release
(ORLANDO) – In what researchers are calling a breakthrough, patients
with thyroid cancer that is resistant to radioactive iodine therapy
were found to respond well to sorafenib, a
researcher reported today at the annual meeting of the American Society
of Clinical Oncology (ASCO). The phase II clinical trial data highlight
an intensive effort at the University of Pennsylvania School of Medicine Abramson Cancer Center to develop effective, personalized therapies for these patients, who have previously had few options for treatment... Read More
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
